Clinical Trial Update: Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adding entinostat to continued aromatase inhibitor therapy in postmenopausal women with ER-positive breast cancer progressing on AI the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• SNDX-275 (entinostat)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: ER+ Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-06-30